Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAgios Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | -$1.87 | -$1.63 | -$1.77 |
| Q2 2025 | 5 | -$1.94 | -$1.72 | -$1.81 |
| Q3 2025 | 6 | -$1.93 | -$1.84 | -$1.90 |
| Q4 2025 | 7 | -$2.08 | -$1.79 | -$1.95 |
| Q1 2026 | 3 | -$2.04 | -$1.75 | -$1.88 |
| Q2 2026 | 1 | -$2.23 | -$1.44 | -$1.87 |
| Q3 2026 | 1 | -$2.11 | -$1.36 | -$1.76 |
| Q4 2026 | 1 | -$2.12 | -$1.37 | -$1.78 |
Agios Pharmaceuticals, Inc. Earnings Date And Information
Agios Pharmaceuticals, Inc. last posted its earnings results on Thursday, October 30th, 2025. The company reported $-1.78 earnings per share for the quarter, topping analysts' consensus estimates of $-1.93 by $0.15. The company had revenue of 12.88 M for the quarter and had revenue of 36.50 M for the year. Agios Pharmaceuticals, Inc. has generated $12 earnings per share over the last year ($11.64 diluted earnings per share) and currently has a price-to-earnings ratio of -3.97. Agios Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 12th, 2026 based on prior year's report dates.
Agios Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2025 | Q3 2025 | -$1.93 | -$1.78 | 0.15 | $10.67 M | $12.88 M |
| 07/31/2025 | Q2 2025 | -$1.74 | -$1.93 | -0.19 | $9.52 M | $12.46 M |
| 05/01/2025 | Q1 2025 | -$1.80 | -$1.55 | 0.25 | N/A | $8.73 M |
| 02/13/2025 | Q4 2024 | -$1.69 | -$1.69 | 0 | N/A | $10.73 M |
| 10/31/2024 | Q3 2024 | $16.69 | $16.65 | -0.04 | $9.44 M | $8.96 M |
| 08/01/2024 | Q2 2024 | -$1.58 | -$1.69 | -0.11 | $9.34 M | $8.62 M |
| 05/02/2024 | Q1 2024 | -$1.64 | -$1.45 | 0.19 | N/A | $8.19 M |
| 02/15/2024 | Q4 2023 | -$1.64 | -$1.72 | -0.08 | N/A | $7.10 M |
| 11/02/2023 | Q3 2023 | -$1.69 | -$1.64 | 0.05 | $7.53 M | $7.40 M |
| 08/03/2023 | Q2 2023 | -$1.60 | -$1.51 | 0.09 | $6.46 M | $6.71 M |
| 05/04/2023 | Q1 2023 | -$1.72 | -$1.30 | 0.42 | $5.24 M | $5.61 M |
| 02/23/2023 | Q4 2022 | -$1.59 | $3.14 | 4.73 | $4.54 M | $4.31 M |
| 11/03/2022 | Q3 2022 | -$1.75 | -$1.32 | 0.43 | $5.27 M | $3.52 M |
| 08/04/2022 | Q2 2022 | -$1.78 | -$1.68 | 0.1 | $2.91 M | $5.58 M |
| 05/05/2022 | Q1 2022 | -$1.85 | -$1.62 | 0.23 | $2.71 M | $832.00 K |
| 02/24/2022 | Q4 2021 | -$1.71 | -$1.74 | -0.03 | $614.70 K | $0 |
| 11/03/2021 | Q3 2021 | -$1.61 | -$1.56 | 0.05 | $2.55 M | $0 |
| 07/29/2021 | Q2 2021 | -$1.39 | -$1.41 | -0.02 | $2.49 M | $0 |
| 04/29/2021 | Q1 2021 | -$1.23 | $26.95 | 28.18 | $47.23 M | $0 |
| 02/25/2021 | Q4 2020 | -$1.41 | -$1.41 | 0 | $39.86 M | $44.05 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Agios Pharmaceuticals, Inc. Earnings: FAQ's
Agios Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 12th, 2026 based offlast year's report dates.
In the previous quarter, Agios Pharmaceuticals, Inc. (:AGIO) reported $-1.78 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.93 by $0.15.
The conference call for Agios Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Agios Pharmaceuticals, Inc.'s latest earnings report can be read online.
Agios Pharmaceuticals, Inc. (:AGIO) has a recorded annual revenue of $36.50 M.
Agios Pharmaceuticals, Inc. (:AGIO) has a recorded net income of $673.73 M.Agios Pharmaceuticals, Inc. has generated $11.86 earnings per share over the last four quarters.
Agios Pharmaceuticals, Inc. (:AGIO) has a price-to-earnings ratio of -3.97 and price/earnings-to-growth ratio is 0.02.